'Thrombolysis' is the breakdown (''lysis'') of
blood clots by
pharmacological means. It is colloquially referred to as ''clot busting'' for this reason. It works by stimulating
fibrinolysis by
plasmin through infusion of analogs of
tissue plasminogen activator, the protein that normally activates plasmin.
Agents
Thrombolysis requires the use of
thrombolytic drugs, which are either derived from ''Streptomyces spp.'' or (more recently) the effect of
recombinant technology, where human activators of
plasminogen (e.g. tissue plasminogen activator, tPA) are manufactured by
bacteria.
Some commonly used thrombolytics are
★
streptokinase
★
urokinase
★
alteplase (recombinant tissue plasminogen activator or ''rtPA'').
★
reteplase
★
tenecteplase
Principles
Formation of blood clots lies at the basis of a number of serious diseases (see below). By breaking down the clot, the disease process can be arrested, or the complications reduced. While other
anticoagulants (such as
heparin) decrease the "growth" of a clot, thrombolytic agents actively ''reduce'' the size of the clot.
All thrombolytic agents work by activating the enzyme
plasminogen, which clears the cross-linked
fibrin mesh (the backbone of a clot). This makes the clot soluble and subject to further
proteolysis by other enzymes, and restores blood flow over occluded
blood vessels.
Uses
Diseases where thrombolysis is used:
★
Myocardial infarction
★
Stroke (ischemic stroke)
★ Massive
pulmonary embolism
★
Acute limb ischaemia
Apart from streptokinase, all thrombolytic drugs are administered together with
heparin (unfractionated or
low molecular weight heparin), usually for 24-48 hours.
Thrombolysis is usually
intravenous. It may also be used during an
angiogram (intra-arterial thrombolysis), e.g. when patients present with stroke beyond three hours.
Contraindications
These are contraindicated in bleeding disorders, active bleeding and when there has been recent surgery.
Diabetic retinopathy is a relative contraindication, as is untreated
high blood pressure.
Warfarin treatment increases risk of bleeding and is a relative contraindication.
Streptokinase is contraindicated in patients who have been previously treated with streptokinase, as there is a risk of
anaphylaxis (life-threatening allergic reaction) due to the production of
antibodies against the enzyme.
References
★
Thrombolysis for acute ischaemic stroke, Wardlaw JM, Zoppo G, Yamaguchi T, Berge E, , , Cochrane Database Syst Rev, 2003